Drugmakers seek risk-averse management amid economic slump

Published: 2009-02-24 06:58:00

Updated: 2009-02-24 06:58:00

The majority of pharmaceutical firms here are expected to become more conservative this year in the wake of the ongoing global credit crunch and economic downturn, strengthening risk management and mobilizing the workforce to full capacity to boost productivity and reduce costs.

Analysts said ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK